Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting
?Data demonstrate KT-413’s potential as a monotherapy and in combination with rituximab or BTK inhibitors, with potent antitumor activity in multiple xenograft models of MYD88MT DLBCL
WATERTOWN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that an abstract featuring new preclinical data for its IRAKIMiD degrader KT-413 has been selected for oral presentation at the 16th Annual International Conference on Malignant Lymphoma virtual meeting, taking place from June 18 - 22, 2021.
“The activity of single-agent targeted therapies, such as BTK inhibitors or IMiDs alone, has been modest in relapsed and refractory DLBCL, necessitating the use of combination therapy," said Jared Gollob, MD, Chief Medical Officer at Kymera Therapeutics. “These data demonstrate the broad and potent antitumor single-agent activity of KT-413 in MYD88MTT DLBCL, combining degradation of both IRAK4 and IMiD substrates Ikaros/Aiolos in a single molecule, along with strongly additive activity in combination with rituximab or BTK inhibitors in MYD88MT OCI-Ly10 xenografts in vivo, suggesting the potential for therapeutically relevant drug combinations in MYD88MT DLBCL.”
Abstract Presentation Details:
About Kymera Therapeutics/strong>
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements